Last reviewed · How we verify
human albumin 5%
Human albumin 5% acts as a volume expander and stabilizer of blood pressure.
Human albumin 5% acts as a volume expander and stabilizer of blood pressure. Used for Severe blood loss or shock, Surgery, Severe burns.
At a glance
| Generic name | human albumin 5% |
|---|---|
| Sponsor | The Cleveland Clinic |
| Drug class | Volume expander |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Human albumin 5% is used to increase blood volume and maintain blood pressure in patients with severe blood loss or shock. It also helps to stabilize the blood volume and prevent shock in patients undergoing surgery or with severe burns.
Approved indications
- Severe blood loss or shock
- Surgery
- Severe burns
Common side effects
- Hypotension
- Anaphylaxis
- Thrombosis
Key clinical trials
- Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1) (PHASE1)
- Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations (PHASE3)
- A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M (PHASE2)
- A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer (PHASE2)
- Allogeneic Human Mesenchymal Stem Cell Infusion for Frailty Patient (NA)
- Prenatal Transplantation for Fetuses With Fanconi Anemia (PHASE1, PHASE2)
- Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP) (PHASE3)
- Safety and Potential Effect of Innovative Treatment by Adjuvant Injection of Stromal Vascular Fraction From Autologous Adipose Tissue of URethral Stenosis With Endoscopic Urethrotomy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- human albumin 5% CI brief — competitive landscape report
- human albumin 5% updates RSS · CI watch RSS
- The Cleveland Clinic portfolio CI